Brooklyn Investment Group Has $700,000 Holdings in Zoetis Inc. (NYSE:ZTS)

Brooklyn Investment Group boosted its stake in Zoetis Inc. (NYSE:ZTS) by 9.3% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,584 shares of the company’s stock after purchasing an additional 304 shares during the period. Brooklyn Investment Group’s holdings in Zoetis were worth $700,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Cetera Investment Advisers increased its stake in shares of Zoetis by 275.2% in the first quarter. Cetera Investment Advisers now owns 96,085 shares of the company’s stock valued at $16,259,000 after buying an additional 70,476 shares during the period. Simplify Asset Management Inc. bought a new position in Zoetis during the third quarter worth $11,684,000. Soltis Investment Advisors LLC acquired a new position in Zoetis in the first quarter valued at $688,000. Bank Pictet & Cie Asia Ltd. raised its position in shares of Zoetis by 41.0% in the 2nd quarter. Bank Pictet & Cie Asia Ltd. now owns 37,500 shares of the company’s stock worth $6,501,000 after acquiring an additional 10,900 shares in the last quarter. Finally, Swedbank AB lifted its stake in shares of Zoetis by 56.2% in the 2nd quarter. Swedbank AB now owns 1,946,277 shares of the company’s stock valued at $337,407,000 after purchasing an additional 700,398 shares during the period. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Trading Up 1.0 %

NYSE:ZTS opened at $178.70 on Tuesday. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $201.92. The firm has a 50-day moving average price of $185.31 and a two-hundred day moving average price of $180.79. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. The firm has a market cap of $80.62 billion, a price-to-earnings ratio of 33.59, a price-to-earnings-growth ratio of 2.71 and a beta of 0.90.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Monday, November 4th. The company reported $1.58 EPS for the quarter, beating analysts’ consensus estimates of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The company had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.29 billion. During the same period last year, the business posted $1.36 earnings per share. Zoetis’s revenue was up 11.6% on a year-over-year basis. On average, equities analysts expect that Zoetis Inc. will post 5.9 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 3rd. Stockholders of record on Thursday, October 31st will be given a dividend of $0.432 per share. This represents a $1.73 dividend on an annualized basis and a dividend yield of 0.97%. The ex-dividend date of this dividend is Thursday, October 31st. Zoetis’s dividend payout ratio is currently 32.52%.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on ZTS. JPMorgan Chase & Co. raised their price objective on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. Piper Sandler upped their price target on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 14th. Stifel Nicolaus upped their target price on Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research report on Wednesday, September 18th. BTIG Research lifted their price target on shares of Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research report on Monday, August 12th. Finally, Argus upgraded shares of Zoetis to a “strong-buy” rating in a report on Friday, August 9th. Ten equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Zoetis has a consensus rating of “Buy” and an average price target of $221.44.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.